Carregant...
From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer
Guardat en:
| Publicat a: | ESMO Open |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMJ Publishing Group
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6735665/ https://ncbi.nlm.nih.gov/pubmed/31555485 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000548 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|